CCPN SPOTLIGHT: BUT IT'S APPROVED IN CANADA, WHY CAN'T I GET IT FOR MY PATIENTS? NAVIGATING MEDICATION ACCESS AND AFFORDABILITY IN CANADA (CCC-199)

Saturday, October 28, 2023

11:00 – 12:00 EST

Location: Palais, 512BF

Target Audience: General: All cardiovascular (clinical and research) health professionals

Chair(s)

Sheri L. Koshman, BScPharm, PharmD, ACPR, FCSHP

Associate Professor
University of Alberta
University of Alberta

Handouts

Presenter(s)

Marc Bains, BBA

Co-Founder & President, HeartLife Foundation of Canada Co-Lead, Canadian Heart Function Alliance
HeartLife Canadian Heart Function Alliance
Marie France Gauthier, PharmD, ACPR, BCCP

Clinical Pharmacist
CCPN
Université de Montréal
Heather Kertland, PharmD, BCCP, FCSHP (she/her/hers)

Clinical Pharmacy Specialist/Leader
CCPN
University of Toronto
Lynette Kosar, BSP, MSc (she/her/hers)

Heart Function Clinic Pharmacist
Saskatchewan Health Authority, CCPN, NAHC
University of Saskatchewan
PO

Paul Oh, MD MSc FRCPC FACP FAACVPR (he/him/his)

Medical Director
University Health Network
University of Toronto
Glen J. Pearson, PharmD, FCCS

Professor of Medicine (Cardiology)
University of Alberta, Faulty of Medicine; Mazankowski Alberta Heart Institute
University of Alberta; Faculty of Medicine & Dentistry
William Semchuk, MSc, PharmD, FCSHP (he/him/his)

Director Clinical Pharmacy Saskatchewan Health Authority
CCPN
University of Saskatchewan

Disclosure(s):

Sheri L. Koshman, BScPharm, PharmD, ACPR, FCSHP: Astra Zencea: Speaker/Honoraria (Terminated, September 28, 2022); HLS: Consultant/Advisory Board (Terminated, October 28, 2023); Novartis: Consultant/Advisory Board (Terminated, March 28, 2021), Speaker/Honoraria (Terminated, March 28, 2021); Pendopharm: Consultant/Advisory Board (Terminated, October 28, 2022); Servier: Consultant/Advisory Board (Terminated, March 6, 2023)

Marc Bains, BBA: AZ: Consultant/Advisory Board (Ongoing); Bayer: Consultant/Advisory Board (Ongoing); BI: Consultant/Advisory Board (Ongoing); BMS: Speaker/Honoraria (Terminated); Novartis: Consultant/Advisory Board (Ongoing); Servier: Speaker/Honoraria (Terminated)

Marie France Gauthier, PharmD, ACPR, BCCP: No financial relationships to disclose

Heather Kertland, PharmD, BCCP, FCSHP: Abbvie: Consultant/Advisory Board (Terminated, December 31, 2022); Novartis: Consultant/Advisory Board (Ongoing); Pharmascience: Consultant/Advisory Board (Ongoing)

Lynette Kosar, BSP, MSc: No financial relationships to disclose

Paul Oh, MD MSc FRCPC FACP FAACVPR: No financial relationships to disclose

Glen J. Pearson, PharmD, FCCS: HLS Therapeutics: Consultant/Advisory Board (Terminated, November 30, 2022); Novartis: Consultant/Advisory Board (Ongoing); Novo NorDisk: Consultant/Advisory Board (Terminated, March 31, 2023); Pharmascience: Consultant/Advisory Board (Terminated, November 30, 2022); Servier: Consultant/Advisory Board (Terminated, November 30, 2022); Trimedic Therapeutics: Consultant/Advisory Board (Ongoing)

William Semchuk, MSc, PharmD, FCSHP: No financial relationships to disclose

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

provide an overview the process by which medications are considered for funding from a national, regional, provincial, and local/institutional perspective;
discuss issues surrounding medication insurance coverage from a system, payor, regional and patient perspective, revealing the challenges and disparities which exist; and
highlight other current issues regarding access including drug shortages, high cost drugs, including rare disease treatments and biosimilars.

Workshop Description: Medications are often the cornerstone of managing many cardiovascular conditions. In Canada, access to these many be impacted by a number of factors including, but not limited to governments, policy and patients. Using vignettes, this session with lead the audience through common scenarios highlighting various issues relating to medication access and affordability. Each vignette will be discussed among panel members to highlight various perspectives. This session will also highlight disparities across Canada with regards to medication access and affordability.
Interactive components will include polling, panel discussion and a Q&A period.